B-intervention	0	9	Denosumab
O	10	18	compared
O	19	23	with
B-control	24	34	zoledronic
I-control	35	39	acid
O	40	43	for
O	44	47	the
O	48	57	treatment
O	58	60	of
B-condition	61	65	bone
I-condition	66	76	metastases
O	77	79	in
O	80	88	patients
O	89	93	with
O	94	102	advanced
O	103	109	breast
O	110	116	cancer
O	116	117	:
O	118	119	a
O	120	130	randomized
O	130	131	,
O	132	138	double
O	138	139	-
O	139	144	blind
O	145	150	study
O	150	151	.

O	152	156	This
O	157	167	randomized
O	168	173	study
O	174	182	compared
O	183	192	denosumab
O	192	193	,
O	194	195	a
O	196	201	fully
O	202	207	human
O	208	218	monoclonal
O	219	227	antibody
O	228	235	against
O	236	244	receptor
O	245	254	activator
O	255	257	of
O	258	265	nuclear
O	266	272	factor
O	273	274	Îº
O	275	276	B
O	277	278	(
O	278	282	RANK
O	282	283	)
O	284	290	ligand
O	290	291	,
O	292	296	with
O	297	307	zoledronic
O	308	312	acid
O	313	315	in
O	316	324	delaying
O	325	327	or
O	328	338	preventing
O	339	347	skeletal
O	347	348	-
O	348	355	related
O	356	362	events
O	363	364	(
O	364	368	SREs
O	368	369	)
O	370	372	in
B-eligibility	373	381	patients
I-eligibility	382	386	with
I-eligibility	387	393	breast
I-eligibility	394	400	cancer
I-eligibility	401	405	with
I-eligibility	406	410	bone
I-eligibility	411	421	metastases
O	421	422	.

O	423	431	Patients
O	432	436	were
O	437	445	randomly
O	446	454	assigned
O	455	457	to
O	458	465	receive
O	466	472	either
O	473	485	subcutaneous
O	486	495	denosumab
O	496	499	120
O	500	502	mg
O	503	506	and
O	507	518	intravenous
O	519	526	placebo
O	527	528	(
O	528	529	n
O	530	531	=
B-intervention-participants	532	533	1
I-intervention-participants	533	534	,
I-intervention-participants	534	537	026
O	537	538	)
O	539	541	or
O	542	553	intravenous
O	554	564	zoledronic
O	565	569	acid
O	570	571	4
O	572	574	mg
O	575	583	adjusted
O	584	587	for
O	588	598	creatinine
O	599	608	clearance
O	609	612	and
O	613	625	subcutaneous
O	626	633	placebo
O	634	635	(
O	635	636	n
O	637	638	=
B-control-participants	639	640	1
I-control-participants	640	641	,
I-control-participants	641	644	020
O	644	645	)
O	646	651	every
O	652	653	4
O	654	659	weeks
O	659	660	.

O	661	664	All
O	665	673	patients
O	674	678	were
O	679	687	strongly
O	688	699	recommended
O	700	702	to
O	703	707	take
O	708	713	daily
O	714	721	calcium
O	722	725	and
O	726	733	vitamin
O	734	735	D
O	736	747	supplements
O	747	748	.

O	749	752	The
O	753	760	primary
O	761	764	end
O	765	770	point
O	771	774	was
B-outcome-Measure	775	779	time
I-outcome-Measure	780	782	to
I-outcome-Measure	783	788	first
I-outcome-Measure	789	791	on
I-outcome-Measure	791	792	-
I-outcome-Measure	792	797	study
I-outcome-Measure	798	801	SRE
O	802	803	(
O	803	810	defined
O	811	813	as
O	814	824	pathologic
O	825	833	fracture
O	833	834	,
O	835	844	radiation
O	845	847	or
O	848	855	surgery
O	856	858	to
O	859	863	bone
O	863	864	,
O	865	867	or
O	868	874	spinal
O	875	879	cord
O	880	891	compression
O	891	892	)
O	892	893	.

O	894	903	Denosumab
O	904	907	was
O	908	916	superior
O	917	919	to
O	920	930	zoledronic
O	931	935	acid
O	936	938	in
O	939	947	delaying
B-outcome	948	952	time
I-outcome	953	955	to
I-outcome	956	961	first
I-outcome	962	964	on
I-outcome	964	965	-
I-outcome	965	970	study
I-outcome	971	974	SRE
O	975	976	(
O	976	982	hazard
O	983	988	ratio
O	988	989	,
O	990	991	0
O	991	992	.
O	992	994	82
O	994	995	;
O	996	998	95
O	998	999	%
O	1000	1002	CI
O	1002	1003	,
O	1004	1005	0
O	1005	1006	.
O	1006	1008	71
O	1009	1011	to
O	1012	1013	0
O	1013	1014	.
O	1014	1016	95
O	1016	1017	;
O	1018	1019	P
O	1020	1021	=
O	1022	1023	.
O	1023	1025	01
O	1026	1037	superiority
O	1037	1038	)
O	1039	1042	and
O	1043	1047	time
O	1048	1050	to
O	1051	1056	first
O	1057	1060	and
O	1061	1071	subsequent
O	1072	1073	(
O	1073	1081	multiple
O	1081	1082	)
O	1083	1085	on
O	1085	1086	-
O	1086	1091	study
O	1092	1096	SREs
O	1097	1098	(
O	1098	1102	rate
O	1103	1108	ratio
O	1108	1109	,
O	1110	1111	0
O	1111	1112	.
O	1112	1114	77
O	1114	1115	;
O	1116	1118	95
O	1118	1119	%
O	1120	1122	CI
O	1122	1123	,
O	1124	1125	0
O	1125	1126	.
O	1126	1128	66
O	1129	1131	to
O	1132	1133	0
O	1133	1134	.
O	1134	1136	89
O	1136	1137	;
O	1138	1139	P
O	1140	1141	=
O	1142	1143	.
O	1143	1146	001
O	1146	1147	)
O	1147	1148	.

B-outcome	1149	1158	Reduction
I-outcome	1159	1161	in
I-outcome	1162	1166	bone
I-outcome	1167	1175	turnover
I-outcome	1176	1183	markers
O	1184	1187	was
O	1188	1195	greater
O	1196	1200	with
O	1201	1210	denosumab
O	1210	1211	.

B-outcome	1212	1219	Overall
I-outcome	1220	1228	survival
O	1228	1229	,
B-outcome	1230	1237	disease
I-outcome	1238	1249	progression
O	1249	1250	,
O	1251	1254	and
O	1255	1260	rates
O	1261	1263	of
B-outcome	1264	1271	adverse
I-outcome	1272	1278	events
I-outcome	1279	1280	(
I-outcome	1280	1283	AEs
I-outcome	1283	1284	)
O	1285	1288	and
B-outcome	1289	1296	serious
I-outcome	1297	1300	AEs
O	1301	1305	were
O	1306	1313	similar
O	1314	1321	between
O	1322	1328	groups
O	1328	1329	.

O	1330	1332	An
O	1333	1339	excess
O	1340	1342	of
B-outcome	1343	1348	renal
I-outcome	1349	1352	AEs
O	1353	1356	and
B-outcome	1357	1362	acute
I-outcome	1362	1363	-
I-outcome	1363	1368	phase
I-outcome	1369	1378	reactions
O	1379	1387	occurred
O	1388	1392	with
O	1393	1403	zoledronic
O	1404	1408	acid
O	1408	1409	;
B-outcome	1410	1422	hypocalcemia
O	1423	1431	occurred
O	1432	1436	more
O	1437	1447	frequently
O	1448	1452	with
O	1453	1462	denosumab
O	1462	1463	.

B-outcome	1464	1477	Osteonecrosis
I-outcome	1478	1480	of
I-outcome	1481	1484	the
I-outcome	1485	1488	jaw
O	1489	1497	occurred
O	1498	1510	infrequently
O	1511	1512	(
B-iv-bin-percent	1512	1513	2
I-iv-bin-percent	1513	1514	.
I-iv-bin-percent	1514	1515	0
I-iv-bin-percent	1515	1516	%
O	1516	1517	,
O	1518	1527	denosumab
O	1527	1528	;
B-cv-bin-percent	1529	1530	1
I-cv-bin-percent	1530	1531	.
I-cv-bin-percent	1531	1532	4
I-cv-bin-percent	1532	1533	%
O	1533	1534	,
O	1535	1545	zoledronic
O	1546	1550	acid
O	1550	1551	;
O	1552	1553	P
O	1554	1555	=
O	1556	1557	.
O	1557	1559	39
O	1559	1560	)
O	1560	1561	.

O	1562	1571	Denosumab
O	1572	1575	was
O	1576	1584	superior
O	1585	1587	to
O	1588	1598	zoledronic
O	1599	1603	acid
O	1604	1606	in
B-outcome	1607	1615	delaying
I-outcome	1616	1618	or
I-outcome	1619	1629	preventing
I-outcome	1630	1634	SREs
O	1635	1637	in
O	1638	1646	patients
O	1647	1651	with
O	1652	1658	breast
O	1659	1665	cancer
O	1666	1676	metastatic
O	1677	1679	to
O	1680	1684	bone
O	1685	1688	and
O	1689	1692	was
O	1693	1702	generally
O	1703	1707	well
O	1708	1717	tolerated
O	1717	1718	.

O	1719	1723	With
O	1724	1727	the
O	1728	1739	convenience
O	1740	1742	of
O	1743	1744	a
O	1745	1757	subcutaneous
O	1758	1767	injection
O	1768	1771	and
O	1772	1774	no
O	1775	1786	requirement
O	1787	1790	for
O	1791	1796	renal
O	1797	1807	monitoring
O	1807	1808	,
O	1809	1818	denosumab
O	1819	1829	represents
O	1830	1831	a
O	1832	1841	potential
O	1842	1851	treatment
O	1852	1858	option
O	1859	1862	for
O	1863	1871	patients
O	1872	1876	with
O	1877	1881	bone
O	1882	1892	metastases
O	1892	1893	.
